Key result
Combining surgical resection and preoperative adriamycin suggests potentially improved prognosis for retroperitoneal sarcoma, warranting further clinical trials.
Why the study?
Does surgical resection combined with preoperative adriamycin improve prognosis in patients with retroperitoneal sarcoma?
Does surgical resection combined with preoperative adriamycin improve prognosis in patients with retroperitoneal sarcoma?
Combining surgical resection with preoperative adriamycin may improve prognosis in retroperitoneal sarcoma, warranting further clinical trials.
This is the authors' abstract. We don't add key points for this paper.
Retroperitoneal sarcoma, regardless of the histopathologic grade of malignancy, has a high incidence of local recurrence that is usually fatal. Surgical resection is mandatory and resectability may be improved by a midline transabdominal approach. However, even with total tumor excision, recurrence is high. A preliminary study, combining resection and preoperative adriamycin, found to be effective for established disease, suggests potentially improved prognosis. Further clinical trials employing combined with adjuvant chemotherapy are warranted.
Answers are grounded in this paper and cite their sources.
Preoperative adriamycin with resection should not yet change practice in retroperitoneal sarcoma; leaves open potential benefit pending prospective trials.
No takes yet. Share an insight, caveat, or question.
Storm et al. (1981) conducted a review in Retroperitoneal sarcoma. Surgical resection and preoperative adriamycin was evaluated on Prognosis and local recurrence. Combining surgical resection and preoperative adriamycin suggests potentially improved prognosis for retroperitoneal sarcoma, warranting further clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: